FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1567133112> ?p ?o ?g. }

• W1567133112 abstract "Neoadjuvant endocrine therapy (ET) in patients (pts) with locally advanced estrogen receptor positive (ER+) breast cancer (BC) improves breast conservation rate, and importantly offers an opportunity for individualized assessment of tumor responsiveness to ET to guide subsequent treatment. Previous neoadjuvant ET trials demonstrated that pathologic tumor size (pT), axillary lymph node status (N), and tumor Ki67 value at surgery predicted risk of relapse. Preoperative endocrine prognostic index (PEPI) was therefore developed to assign risk scores based on these factors. Modified PEPI 0, defined by pT1-2 N0 Ki67 ALTERNATE trial is a three-arm phase III neoadjuvant/adjuvant ET trial designed to achieve two primary objectives. The first is to prospectively validate that modified PEPI 0 predicts > 95% relapse-free survival (RFS). The second is to determine whether fulvestrant (F), or fulvestrant (F) plus anastrozole (A), is superior to A in inducing a higher rate of modified PEPI 0. Secondary objectives include assessing RFS for pts with endocrine resistant tumor, defined by Ki67 > 10% at 4 or 12 wk, disease progression, or modified PEPI non-0, and pathologic responses of resistant tumors to neoadjuvant chemotherapy. Correlative studies include degrees of Ki67 suppression and ER level post treatment. In addition, ongoing research sequencing studies of DNA and RNA will be performed to contrast sensitive vs resistant tumors. During the first phase of the trial, 1200 pts are randomized 1:1:1 to the F, A or F/A. This provides an 82% chance, 1-sided alpha 0.025 chi-square test to detect at least 10% difference in modified PEPI 0 rate comparing F or F/A with A. While waiting for result of analysis, the A arm will continue for the 2 nd phase enrollment. Only the F-containing arm(s) superior over A will be continued to the 2 nd phase. During the 2 nd phase, an additional 540 pts in each arm is estimated to obtain 317 pts with PEPI score 0. This will have a 90% chance, with a one-sided alpha=0.025 nonparametric Brookmeyer-Crowley type one sample survival test, rejecting that 5 year RFS rate is 95%. The maximum sample size is 2820 pts. Eligible pts include postmenopausal women with newly diagnosed clinical stage II or III ER+ (Allred score 6-8) HER2- BC. Tumor biopsy is required at baseline, 4 wk, and surgery for central Ki67 analysis. Treatment decision is individualized based on 4 wk Ki67 and modified PEPI score. Pts with Ki67 > 10% at 4 wk are switched to chemotherapy. Pts with a modified PEPI score of 0 are recommended not to receive chemotherapy, but continue the assigned ET for 1.5 years followed by 3 years of A. This trial is currently accruing pts through CTSU. This research is supported in part by NCI BIQSFP, and grants from Breast Cancer Research Foundation, Genentech, and the Investigator-Sponsored Study Program of AstraZeneca. The Clinical Trials.gov Identifier: NCT01953588. Citation Format: Cynthia X Ma, Vera Suman, A Marilyn Leitch, Souzan Sanati, Katherine DeSchryver, Gary W Unzeitig, Paul Haluska, Mark Watson, Olwen Hahn, Jo Anne Zujewski, Kelly Hunt, Eric P Winer, Cliff A Hudis, Matthew J Ellis. Alliance A011106: ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A phase III study [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr OT2-1-04." @default.
• W1567133112 created "2016-06-24" @default.
• W1567133112 creator A5006471068 @default.
• W1567133112 creator A5006700202 @default.
• W1567133112 creator A5009199118 @default.
• W1567133112 creator A5017326158 @default.
• W1567133112 creator A5017411324 @default.
• W1567133112 creator A5017670549 @default.
• W1567133112 creator A5027691610 @default.
• W1567133112 creator A5056136815 @default.
• W1567133112 creator A5057135409 @default.
• W1567133112 creator A5068394117 @default.
• W1567133112 creator A5070245248 @default.
• W1567133112 creator A5082661564 @default.
• W1567133112 creator A5085083246 @default.
• W1567133112 creator A5089153267 @default.
• W1567133112 date "2015-04-30" @default.
• W1567133112 modified "2023-09-27" @default.
• W1567133112 title "Abstract OT2-1-04: Alliance A011106: ALTernate approaches for clinical stage II or III Estrogen Receptor positive breast cancer NeoAdjuvant TrEatment (ALTERNATE) in postmenopausal women: A phase III study" @default.
• W1567133112 doi "https://doi.org/10.1158/1538-7445.sabcs14-ot2-1-04" @default.
• W1567133112 hasPublicationYear "2015" @default.
• W1567133112 type Work @default.
• W1567133112 sameAs 1567133112 @default.
• W1567133112 citedByCount "0" @default.
• W1567133112 crossrefType "proceedings-article" @default.
• W1567133112 hasAuthorship W1567133112A5006471068 @default.
• W1567133112 hasAuthorship W1567133112A5006700202 @default.
• W1567133112 hasAuthorship W1567133112A5009199118 @default.
• W1567133112 hasAuthorship W1567133112A5017326158 @default.
• W1567133112 hasAuthorship W1567133112A5017411324 @default.
• W1567133112 hasAuthorship W1567133112A5017670549 @default.
• W1567133112 hasAuthorship W1567133112A5027691610 @default.
• W1567133112 hasAuthorship W1567133112A5056136815 @default.
• W1567133112 hasAuthorship W1567133112A5057135409 @default.
• W1567133112 hasAuthorship W1567133112A5068394117 @default.
• W1567133112 hasAuthorship W1567133112A5070245248 @default.
• W1567133112 hasAuthorship W1567133112A5082661564 @default.
• W1567133112 hasAuthorship W1567133112A5085083246 @default.
• W1567133112 hasAuthorship W1567133112A5089153267 @default.
• W1567133112 hasConcept C121608353 @default.
• W1567133112 hasConcept C126322002 @default.
• W1567133112 hasConcept C143998085 @default.
• W1567133112 hasConcept C146357865 @default.
• W1567133112 hasConcept C151730666 @default.
• W1567133112 hasConcept C2776215463 @default.
• W1567133112 hasConcept C2777176818 @default.
• W1567133112 hasConcept C2778292576 @default.
• W1567133112 hasConcept C2780482068 @default.
• W1567133112 hasConcept C29456083 @default.
• W1567133112 hasConcept C530470458 @default.
• W1567133112 hasConcept C71924100 @default.
• W1567133112 hasConcept C84606932 @default.
• W1567133112 hasConcept C86803240 @default.
• W1567133112 hasConceptScore W1567133112C121608353 @default.
• W1567133112 hasConceptScore W1567133112C126322002 @default.
• W1567133112 hasConceptScore W1567133112C143998085 @default.
• W1567133112 hasConceptScore W1567133112C146357865 @default.
• W1567133112 hasConceptScore W1567133112C151730666 @default.
• W1567133112 hasConceptScore W1567133112C2776215463 @default.
• W1567133112 hasConceptScore W1567133112C2777176818 @default.
• W1567133112 hasConceptScore W1567133112C2778292576 @default.
• W1567133112 hasConceptScore W1567133112C2780482068 @default.
• W1567133112 hasConceptScore W1567133112C29456083 @default.
• W1567133112 hasConceptScore W1567133112C530470458 @default.
• W1567133112 hasConceptScore W1567133112C71924100 @default.
• W1567133112 hasConceptScore W1567133112C84606932 @default.
• W1567133112 hasConceptScore W1567133112C86803240 @default.
• W1567133112 hasLocation W15671331121 @default.
• W1567133112 hasOpenAccess W1567133112 @default.
• W1567133112 hasPrimaryLocation W15671331121 @default.
• W1567133112 isParatext "false" @default.
• W1567133112 isRetracted "false" @default.
• W1567133112 magId "1567133112" @default.
• W1567133112 workType "article" @default.